GlassScriptPhysician profile
James Morgan
NPI 1578018107
$5,369.61
in general payments reported to CMS, 2019-2025
13 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $671 · 2023: $1,244 · 2024: $1,113 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,986.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,331.55 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,311.99 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $585.50 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $467.41 | 2023-2025 | Rexulti |
| Alkermes, INC. | $419.85 | 2023-2025 | Aristada, Lybalvi |
| Abbvie INC. | $381.58 | 2023-2025 | |
| Lundbeck LLC | $330.44 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $287.77 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $95.79 | 2021-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $73.92 | 2025 | Hetlioz, Fanapt |
| Corium, LLC | $35.65 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $27.57 | 2024 | Spravato |
| Almatica Pharma LLC | $20.59 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.